While the mTOR inhibitor IDELALISIB, which is currently approved for the treatment of cancer with specific pharmacologic agents, has not been successful [79], inhibitors that inhibit both PI3K/mTOR have shown good results by inducing apoptosis as well as inhibiting autophagy [57]. The gene discussed is MTOR; the disease is cancer.